Beyond prediction: unveiling the prognostic power of μ-opioid and cannabinoid receptors, alongside immune mediators, in assessing the severity of SARS-CoV-2 infection

Table 2 ROC curve for predicting severity in patients with SARS-CoV-2 via assessing immune relating factors

Variable	Group	Sub-Groups	Cutoff point	Sensitivity (%)	Specificity (%)	AUC	P-value	95% CI Lower Bound	95% CI Upper Bound
CB2	Female	Severe Vs. Non-Severe	> 0.151	94	60	0.74	0.04	0.54	0.93
CB2	Male	Severe Vs. Non-Severe	> 0.242	84	62	0.76	0.02	0.58	0.94
MOR	Female	Severe Vs. Non-Severe	> 0.211	66	60	0.72	0.06	0.51	0.92
MOR	Male	Severe Vs. Non-Severe	> 0.295	84	64	0.74	0.04	0.53	0.94
lL-17	Female	Severe Vs. Non-Severe	> 35.44	94	86	0.97	0.0001	0.91	1
lL-17	Male	Severe Vs. Non-Severe	> 42.91	87	67	0.75	0.01	0.57	1
MCP-1	Female	Severe Vs. Non-Severe	> 67.70	100	86	0.93	0.0001	0.82	1
MCP-1	Male	Severe Vs. Non-Severe	> 97.65	83	65	0.80	0.04	0.58	1
OPN	Female	Severe Vs. Non-Severe	> 17.84	94	86	0.98	0.0001	0.94	1
OPN	Male	Severe Vs. Non-Severe	> 18.26	85	60	0.89	0.0001	0.77	1
IFN-γ	Female	Severe Vs. Non-Severe	> 333	94	93	0.93	0.0001	0.93	1
IFN-γ	Male	Severe Vs. Non-Severe	> 350	81	67	0.76	0.04	0.54	0.98

In Table, the Receiver Operating Characteristic (ROC) curve information for CB2, MOR, IL-17, MCP-1, OPN, and IFN-γ in discriminating between severe and non-severe groups of SARS-CoV-2 patients is presented. Key details include:
Cutoff points indicating the threshold values for each biomarker
Sensitivity (%) and Specificity (%) values reflecting the diagnostic accuracy of the biomarkers
The Area Under the Curve (AUC) representing the overall performance of the biomarker in distinguishing between severe and non-severe cases
P-values indicating the statistical significance of the AUC values
Confidence interval (CI) displays the probability that a parameter will fall between a pair of values around the mean
These metrics provide valuable insights into the discriminatory power of the biomarkers studied, aiding in the assessment of their predictive potential for SARS-CoV-2 infection severity

ISSN: 1471-2334